ID

13603

Beschreibung

Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00510939

Link

https://clinicaltrials.gov/show/NCT00510939

Stichworte

  1. 19.02.16 19.02.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

19. Februar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Acute Myeloid Leukemia NCT00510939

Eligibility Acute Myeloid Leukemia NCT00510939

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. provision of written informed consent
Beschreibung

1. provision of written informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
2. male or female aged >18 years with newly diagnosed acute myeloid leukemia (aml), de novo or secondary, unfit for conventional chemotherapy
Beschreibung

2. male or female aged >18 years with newly diagnosed acute myeloid leukemia (aml), de novo or secondary, unfit for conventional chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C1518321
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C3841806
3. male or female with acute myeloid leukemia in first relapse ( > 60 years)
Beschreibung

3. male or female with acute myeloid leukemia in first relapse ( > 60 years)

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0035020
UMLS CUI [2]
C0001779
4. who performance status ³ 2, or/and unwillingness to receive conventional chemotherapy
Beschreibung

4. who performance status ³ 2, or/and unwillingness to receive conventional chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C1298650
UMLS CUI [2]
C0392920
5. negative pregnancy test or evidence of post-menopausal status for female patients.
Beschreibung

negative pregnancy test or evidence of post-menopausal status for female patients.

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0232970
6. rasgrp1/aptx gene expression ratio calculated at the screening >10 (part b.2 only)
Beschreibung

6. rasgrp1/aptx gene expression ratio calculated at the screening >10 (part b.2 only)

Datentyp

boolean

Alias
UMLS CUI [1]
C1419283
UMLS CUI [2]
C1423885
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. serum bilirubin 2 x> upper limit of normal (uln)
Beschreibung

1. serum bilirubin 2 x> upper limit of normal (uln)

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln
Beschreibung

2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln

Datentyp

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault)
Beschreibung

3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault)

Datentyp

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0373595
4. patients with aml of fab m3 classification (apl)
Beschreibung

4. patients with aml of fab m3 classification (apl)

Datentyp

boolean

Alias
UMLS CUI [1]
C0023487
5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission
Beschreibung

5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
6. any clinically defined central nervous system aml.
Beschreibung

6. any clinically defined central nervous system aml.

Datentyp

boolean

Alias
UMLS CUI [1]
C1332884
UMLS CUI [2]
C0023467
7. participation in an investigational drug study within the 30 days prior to entry
Beschreibung

7. participation in an investigational drug study within the 30 days prior to entry

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
8. evidence of uncontrolled infection or cns-hemorrhagic
Beschreibung

8. evidence of uncontrolled infection or cns-hemorrhagic

Datentyp

boolean

Alias
UMLS CUI [1]
C0009488
9. patients with documented cases of human immunodeficiency virus (hiv)
Beschreibung

9. patients with documented cases of human immunodeficiency virus (hiv)

Datentyp

boolean

Alias
UMLS CUI [1]
C0019682
10. peripheral neuropathy or neuropathic pain grade > or = 2
Beschreibung

10. peripheral neuropathy or neuropathic pain grade > or = 2

Datentyp

boolean

Alias
UMLS CUI [1]
C0031117
UMLS CUI [2]
C0458960
11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
Beschreibung

11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0006030
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0024730
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0019134
12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
Beschreibung

12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis

Datentyp

boolean

Alias
UMLS CUI [1]
C0018799
13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only)
Beschreibung

13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only)

Datentyp

boolean

Alias
UMLS CUI [1]
C1419283
UMLS CUI [2]
C1423885

Ähnliche Modelle

Eligibility Acute Myeloid Leukemia NCT00510939

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
written informed consent
Item
1. provision of written informed consent
boolean
C0021430 (UMLS CUI [1])
age, aml, unfit for conventional chemotherapy
Item
2. male or female aged >18 years with newly diagnosed acute myeloid leukemia (aml), de novo or secondary, unfit for conventional chemotherapy
boolean
C0001779 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C1518321 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3,1])
C3841806 (UMLS CUI [3,2])
aml in first relapse
Item
3. male or female with acute myeloid leukemia in first relapse ( > 60 years)
boolean
C0023467 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
who performance status
Item
4. who performance status ³ 2, or/and unwillingness to receive conventional chemotherapy
boolean
C1298650 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
negative pregnancy test or evidence of post-menopausal status for female patients.
Item
5. negative pregnancy test or evidence of post-menopausal status for female patients.
boolean
C0032961 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
rasgrp1/aptx gene expression ratio
Item
6. rasgrp1/aptx gene expression ratio calculated at the screening >10 (part b.2 only)
boolean
C1419283 (UMLS CUI [1])
C1423885 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
serum bilirubin
Item
1. serum bilirubin 2 x> upper limit of normal (uln)
boolean
C1278039 (UMLS CUI [1])
ast and alt
Item
2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
creatinine and creatinine clearance
Item
3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault)
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
apl
Item
4. patients with aml of fab m3 classification (apl)
boolean
C0023487 (UMLS CUI [1])
malignancy
Item
5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission
boolean
C0006826 (UMLS CUI [1])
central nervous system aml
Item
6. any clinically defined central nervous system aml.
boolean
C1332884 (UMLS CUI [1])
C0023467 (UMLS CUI [2])
participation status
Item
7. participation in an investigational drug study within the 30 days prior to entry
boolean
C2348568 (UMLS CUI [1])
uncontrolled infection or cns-hemorrhagic
Item
8. evidence of uncontrolled infection or cns-hemorrhagic
boolean
C0009488 (UMLS CUI [1])
hiv
Item
9. patients with documented cases of human immunodeficiency virus (hiv)
boolean
C0019682 (UMLS CUI [1])
peripheral neuropathy or neuropathic pain
Item
10. peripheral neuropathy or neuropathic pain grade > or = 2
boolean
C0031117 (UMLS CUI [1])
C0458960 (UMLS CUI [2])
hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
Item
11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
boolean
C0020517 (UMLS CUI [1,1])
C0006030 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0019134 (UMLS CUI [3,2])
cardiac disease
Item
12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
boolean
C0018799 (UMLS CUI [1])
rasgrp1/aptx gene expression ratio
Item
13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only)
boolean
C1419283 (UMLS CUI [1])
C1423885 (UMLS CUI [2])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video